CU Boulder startup Arpeggio Biosciences raises $17M in Series A funding led by builders VC

Arpeggio Biosciences raises $17M in Series A funding led by builders VC

Sept. 20, 2022

Arpeggio’s technology isolates a drug’s effect on entire transcriptomes and has identified new modulators of hard-to-drug proteins like transcription factors. Funding was led by Builders VC and will support ongoing development of Arpeggio’s drug pipeline as well as its transcription-monitoring technologies.

ColdQuanta named Top Company 2022 by ColoradoBiz

ColdQuanta named Top Company 2022 by ColoradoBiz

Sept. 13, 2022

This year’s Top Company winners and finalists represent 13 industry categories. Entrants were judged on three criteria: outstanding achievement, financial performance and community involvement. ColdQuanta won in the "Technology, Software & Communications" category.

PhET Interactive Simulations: Putting students in the driver’s seat of STEM learning

PhET Interactive Simulations: Putting students in the driver’s seat of STEM learning

Sept. 10, 2022

It's hard to find a physics or chemistry teacher that doesn't use PhET Interactive Simulations, a free online science and math simulations platform founded at CU Boulder in 2002 by Nobel Laureate Carl Wieman. These beautifully designed STEM explorations are loved by students and educators alike.

How this celebrity tattoo artist created a tattoo you can turn on and off at will

How this celebrity tattoo artist created a tattoo you can turn on and off at will

Sept. 8, 2022

Keith “Bang Bang” McCurdy is taking HYPRSKN—the microscopic skin implants with adaptive, color-changing in-skin pigments developed by Carson Bruns and Jesse Butterfield of CU Boulder's ATLAS Institute—to the next level with real tattoo ink that you can “turn on” or off using different wavelengths of UV and white light.

ColdQuanta acquires Chicago-based quantum startup Super.tech

ColdQuanta acquires Chicago-based quantum startup Super.tech

Aug. 25, 2022

The merger is addressing pressing needs in quantum research for CU Boulder spinout ColdQuanta—as well as the quantum industry. Both companies are affiliates of Q-NEXT, a U.S. Department of Energy (DOE) National Quantum Information Science Research Center led by Argonne National Laboratory.

CU Boulder spinout Think Bioscience raises $17M to target undruggable proteins

CU Boulder spinout Think Bioscience raises $17M to target undruggable proteins

Aug. 18, 2022

Think Bioscience (“Think”), a synthetic biology company focused on developing small-molecule therapeutics that target difficult-to-drug proteins, has raised $17M in an oversubscribed Seed round. Think's foundational IP was developed by CEO Jerome Fox's research group at CU Boulder.

This carbon-neutral, biogenic cement Is the future of infrastructure

This carbon-neutral, biogenic cement is the future of infrastructure

Aug. 11, 2022

“For the industry, now is the time to solve this problem,” Wil Srubar, an associate professor at CU Boulder and the lead researcher on the project, says in a news release. “We believe that we have one of the best solutions, if not the best solution, for the cement and concrete industry to address its carbon problem.”

Darwin Biosciences announced as a finalist for the Medical Innovation Challenge

Darwin Biosciences announced as a finalist for the Medical Innovation Challenge

Aug. 11, 2022

The CU Boulder startup, which creates accessible diagnostics for the early detection of disease, will pitch at the Defense TechConnect Innovation Summit for $200K in non-dilutive awards. Challenge finalists represent health and biotech innovation with dual use for civilian and national security applications.

Artimus Robotics secures $3.5M in grants, contracts

Artimus Robotics secures $3.5M in grants, contracts

July 28, 2022

Artimus builds actuator components for industries such as defense, automotive and medical devices. Its proprietary HASEL technology “already has shown incredible potential in many applications,” said CEO Tim Morrissey. “This capital will facilitate optimization of the technology for the best applications.”

SomaLogic acquires DNA nanotechnology leader Palamedrix

SomaLogic acquires DNA nanotechnology leader Palamedrix

July 26, 2022

SomaLogic, a leader in AI data-driven proteomics technology founded by Professor Larry Gold (MCDB), has entered into an agreement to acquire Palamedrix, Inc.—a move intended to accelerate the SomaScan Platform's utilization in global biopharma and academic markets.

Pages